14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
PACS vs ENSG: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, The Ensign Group, Inc. (ENSG) is the stronger overall head-to-head candidate over PACS Group, Inc. (PACS) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). PACS carries a Unified Composite Score of 46.8/100 (HOLD) at $43.67 (15.3x Forward P/E, 7.4% operating margin), whereas ENSG carries 48.3/100 (HOLD) at $176.32 (20.1x Forward P/E, 8.8% operating margin).
Competes within the Medical Care Facilities value chain with $10.3B market capitalization and 8.8% operating margin.
OpEx & R&D Reinvestment8.3% of Rev ($471M)
90D Engineering Disclosures0 Published
Investor FAQ PACS vs ENSG Key Questions & Quantitative Answers
As of Nov 20, 2026, The Ensign Group, Inc. (ENSG) is the stronger overall head-to-head candidate over PACS Group, Inc. (PACS) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). PACS carries a Unified Composite Score of 46.8/100 (HOLD) at $43.67 (15.3x Forward P/E, 7.4% operating margin), whereas ENSG carries 48.3/100 (HOLD) at $176.32 (20.1x Forward P/E, 8.8% operating margin). Technically, PACS sits in a Neutral phase (RSI 39.2, CONSOLIDATION options structure) and ENSG sits in a Neutral phase (RSI 43.5, CONSOLIDATION options structure).
ENSG leads the Growth & Scale pillar: PACS posts +11.5% YoY revenue growth and +15.6% YoY earnings growth on $5.71B TTM revenue (17.8% gross margin, 7.4% operating margin), compared with ENSG at +14.5% YoY revenue growth and +23.9% YoY earnings growth on $5.67B TTM revenue (17.1% gross margin, 8.8% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), PACS cumulative revenue shifted +120.4% while ENSG shifted +187.4%. In operating R&D and SG&A reinvestment, PACS deploys 10.4% of Rev ($593M) (0 90-day corporate R&D disclosures) versus 8.3% of Rev ($471M) (0 disclosures) for ENSG.
PACS screens cheaper on headline valuation multiples. PACS trades at 15.3x Forward P/E, 26.2x Trailing P/E, 1.22x PEG, and 1.8x EV/Revenue (0.1% FCF margin), whereas ENSG trades at 20.1x Forward P/E, 26.3x Trailing P/E, 1.40x PEG, and 2.2x EV/Revenue (3.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PACS (26.5% ROE) versus ENSG (17.1% ROE) capital efficiency.
In options market volatility and institutional positioning, PACS carries 46.1% implied volatility (11th %ile, Compressed (<25th %ile)), a 0.52x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.78β · 51% Vol realized risk). By comparison, ENSG carries 99.5% implied volatility (62nd %ile, Elevated (60th–80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.12β · 42% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.